HRT Price Prediction, HireRight Holdings Corp AI Recommendations

HRT in -13.15% downward trend, declining for three consecutive days on June 29, 2022

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HRT declined for three days, in 86 of 110 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 28, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on HRT as a result. In of 61 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HRT turned negative on June 29, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 27 similar instances when the indicator turned negative. In of the 27 cases the stock turned lower in the days that followed. This puts the odds of success at .

HRT moved below its 50-day moving average on June 28, 2022 date and that indicates a change from an upward trend to a downward trend.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRT advanced for three days, in of 101 cases, the price rose further within the following month. The odds of a continued upward trend are .

HRT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 65 cases where HRT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. HRT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.452) is normal, around the industry mean (6.345). P/E Ratio (500.000) is within average values for comparable stocks, (144.137). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.839). HRT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.459) is also within normal values, averaging (2.466).

HRT is expected to report earnings to fall 8.03% to 34 cents per share on August 31

Q2'22

Est.

$0.34

Q1'22

Beat

by $0.14

Q4'21

Beat

by $0.25

Q3'21

Beat

by $0.02